CD8-positive T-cell
A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer.
A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer. CD8 strengthens interactions between the T-cell receptor and peptide–major histocompatibility complex class I (MHC I) molecules displayed by nucleated cells. Following antigen recognition and appropriate co-stimulation, CD8⁺ T cells can differentiate into cytotoxic effector cells, memory T cells, or dysfunctional/exhausted states. Effector CD8⁺ T cells eliminate infected or transformed cells through cytotoxic granules and death-receptor pathways and can produce cytokines such as interferon gamma and Tumor necrosis factor-α (TNF-α).
CD8⁺ T cells are central components of antiviral and antitumor immunity. Their activity is shaped by antigen-presenting cells, particularly dendritic cells capable of cross-priming, as well as by the tumor microenvironment, regulatory T cells, macrophages, transforming growth factor, metabolic conditions, and immune-checkpoint pathways. In cancer, CD8⁺ T cells may recognize tumor-associated or tumor-specific antigens, but their function can be limited by inhibitory receptors such as LAG3 and TIGIT, suppressive signaling involving CD274 molecule, nutrient competition, and lactate accumulation. These properties make CD8⁺ T cells important targets and effectors of immunotherapy, including adoptive tumor-infiltrating lymphocyte (TIL) therapy, checkpoint inhibitor treatment, cytokine-based agents, and approaches designed to improve dendritic-cell priming.
Where the papers sit
10 papers from the last 6 months study CD8-positive T-cell directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 human data · 8 preclinical · 1 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Mechanisms of T-Cell Immunotherapy
Cytoskeletal remodeling and matrix stiffening are emerging as barriers to CD8 T-cell immunotherapy. Cofilin1 and LOXL4 affect response through T-cell structure and the tumor matrix, while acetyldigoxin can restore function in lung cancer. AAV delivery is also being examined for rapid, promoter-dependent T-cell activation. The field is moving toward combining immune modulation with strategies that alter tissue barriers and delivery responses.
3 papers · 30%
-
Tumor T-Cell Exhaustion
Tumor-reactive CD8 T cells are being defined by divergent fates, from terminal exhaustion to durable memory. LAG3 and TIGIT remain central targets, with a TIGIT-directed IL-12 fusion protein combining checkpoint engagement with NK- and T-cell stimulation. TGR5-dependent dendritic-cell cross-priming adds an antigen-presentation strategy to checkpoint approaches. Treatment is therefore moving beyond single-checkpoint blockade toward coordinated activation and priming.
3 papers · 30%
-
Others — Interferon-Linked T-Cell Immunity
Interferon signaling, checkpoint-defined T-cell states and metabolic stress are linked to CD8 T-cell activity across tumors and inflammatory disease. PD-1 and LAG-3 expression can mark clonally expanded cells with favorable gastric-cancer prognosis, while cuproptosis is being explored as a route to overcome immunotherapy resistance. Local interferon delivery may restore antigen presentation and sensitize medulloblastoma to T-cell killing. CX3CR1-positive clonal expansion in anti-NMDA receptor encephalitis broadens the set toward autoimmune neuroinflammation, leaving no single therapeutic direction.
4 papers · 40%
CD8-positive T cells can create, rather than merely exploit, tumor-cell susceptibility to therapy
The medulloblastoma model studied by the local-interferon delivery paper and the cuproptosis-immunity systems studied by the cuproptosis paper both replace the usual one-way picture in which CD8-positive T cells act only as downstream killers of tumor cells. In medulloblastoma, CD8-derived IFN-γ restores tumor-cell MHC class I and thereby enables T-cell killing; in cuproptosis models, the same cytokine induces tumor-cell FDX1 and increases sensitivity to cuproptosis, while cuproptotic death further stimulates antitumor immunity 42735303Sep 42330950Jun. The resulting change is conceptual as well as therapeutic: CD8-positive T-cell activity is itself a mechanism for remodeling tumor vulnerability and can determine whether otherwise ineffective tumor-directed treatments work.
CD8-positive T cells are identified as clonally expanded pathogenic effectors in anti-NMDA receptor encephalitis
The anti-NMDA receptor encephalitis study uses single-cell transcriptomic, T-cell-receptor and epitope profiling to assign CD8-positive T cells a disease-driving role outside the set's dominant tumor-immunity and therapeutic-response frameworks. It identifies clonally expanded CX3CR1-expressing CD8-positive T cells in cerebrospinal fluid as disease-associated effectors with predicted GluN1-epitope reactivity, cytotoxic and proinflammatory programs, and interaction with activated B cells, rather than treating them as incidental immune participants 42711907Sep. This redirects attention toward CD8-positive T cells as potential mediators of autoimmune neuroinflammation and therapeutic resistance in anti-NMDA receptor encephalitis.
Papers
The 10 papers from the last 6 months that study CD8-positive T-cell directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Mechanisms of T-Cell Immunotherapy (3)
- Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer. Science advances · 11 Sept 2026 PMID 42726857
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
- CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. JCI insight · 9 Jun 2026 PMID 42262864
Tumor T-Cell Exhaustion (3)
- Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells. The Journal of experimental medicine · 18 Aug 2026 PMID 42611047
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. Signal transduction and targeted therapy · 26 Jul 2026 PMID 42503514
- TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine · 16 Jun 2026 PMID 42302794
Others — Interferon-Linked T-Cell Immunity (4)
- Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
- Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. Proceedings of the National Academy of Sciences of the United States of America · 14 Sept 2026 PMID 42735303
- Single-Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti-NMDA Receptor Encephalitis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Sept 2026 PMID 42711907
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
By study type
Human data, design not indexed (1)
- Intratumoral PD-1+LAG-3+CD8+ T cells are associated with improved prognosis in gastric cancer. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742874
Preclinical: animal, cell and lab studies (8)
- Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. Proceedings of the National Academy of Sciences of the United States of America · 14 Sept 2026 PMID 42735303
- Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer. Science advances · 11 Sept 2026 PMID 42726857
- Tumor-reactive LAG3+CD8+ T cells diverge into terminally exhausted cells and long-lived memory T cells. The Journal of experimental medicine · 18 Aug 2026 PMID 42611047
- Cofilin1-driven cytoskeletal remodeling modulates pan-cancer CD8+ T cell immunotherapy responses. Cell reports. Medicine · 12 Aug 2026 PMID 42586064
- Chenodeoxycholic acid restrains tumor growth via TGR5-dependent type 1 dendritic cells cross-priming. Signal transduction and targeted therapy · 26 Jul 2026 PMID 42503514
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. Cell reports. Medicine · 16 Jun 2026 PMID 42302794
- CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity. JCI insight · 9 Jun 2026 PMID 42262864
Unclassified: not yet indexed with MeSH (1)
- Single-Cell Profiling Reveals Clonally Expanded CX3CR1+ T Cells in Anti-NMDA Receptor Encephalitis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Sept 2026 PMID 42711907
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.